SETD9

Across TCGA pan-cancer cohorts, SETD9 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SETD9 data layer compared with 20 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher SETD9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SETD9 expression acts as an unfavorable survival marker.

CESC, HNSC, and LIHC are the cancer types where SETD9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
HNSC	OS	Median	III,IV	0.154	0.656	.017	12	view →
LIHC	DFS	Median	II,III,IV	0.046	0.427	<.001	12	view →
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SETD9–CESC (DFS)

Open the CESC breakdown →